Menu
Search
|

Menu

Close
X

Anthera Pharmaceuticals Inc ANTH.OQ (NASDAQ Stock Exchange Capital Market)

1.69 USD
-0.03 (-1.74%)
As of Feb 17
chart
Previous Close 1.72
Open 1.75
Volume 43,685
3m Avg Volume 74,096
Today’s High 1.75
Today’s Low 1.65
52 Week High 6.23
52 Week Low 1.21
Shares Outstanding (mil) 10.91
Market Capitalization (mil) 18.00
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
3
EPS (USD)
FY17
-2.573
FY16
-12.833
FY15
-7.994
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
4.14
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-321.65
14.43
Return on Equity (TTM)
vs sector
-434.34
16.13

EXECUTIVE LEADERSHIP

Paul Truex
Executive Chairman of the Board, Since 2016
Salary: $515,000.00
Bonus: $401,718.00
Craig Thompson
President, Chief Executive Officer, Chief Operating Officer, Director, Since 2016
Salary: --
Bonus: --
May Liu
Senior Vice President - Finance and Administration, Principal Accounting Officer, Since 2013
Salary: $261,000.00
Bonus: $89,752.00
Patrick Murphy
Senior Vice President - Manufacturing, Since 2018
Salary: --
Bonus: --
William Shanahan
Chief Medical Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

25801 Industrial Blvd Ste B
HAYWARD   CA   94545-2223

Phone: +1510.8565600

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

SPONSORED STORIES